MX2023012483A - Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico. - Google Patents

Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.

Info

Publication number
MX2023012483A
MX2023012483A MX2023012483A MX2023012483A MX2023012483A MX 2023012483 A MX2023012483 A MX 2023012483A MX 2023012483 A MX2023012483 A MX 2023012483A MX 2023012483 A MX2023012483 A MX 2023012483A MX 2023012483 A MX2023012483 A MX 2023012483A
Authority
MX
Mexico
Prior art keywords
treatment
chronic pain
pharmaceutical formulations
transdermal pharmaceutical
transdermal
Prior art date
Application number
MX2023012483A
Other languages
English (en)
Spanish (es)
Inventor
Tamanna Lather
Fotios M Plakogiannis
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of MX2023012483A publication Critical patent/MX2023012483A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023012483A 2021-04-22 2022-04-21 Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico. MX2023012483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163177981P 2021-04-22 2021-04-22
PCT/IB2022/053730 WO2022224184A1 (en) 2021-04-22 2022-04-21 Transdermal pharmaceutical formulations for the treatment of chronic pain

Publications (1)

Publication Number Publication Date
MX2023012483A true MX2023012483A (es) 2023-11-03

Family

ID=83722736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012483A MX2023012483A (es) 2021-04-22 2022-04-21 Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.

Country Status (8)

Country Link
US (1) US20220347151A1 (https=)
EP (1) EP4326252A4 (https=)
JP (1) JP2024514362A (https=)
CN (1) CN117545478A (https=)
AU (1) AU2022260813A1 (https=)
CA (1) CA3215685A1 (https=)
MX (1) MX2023012483A (https=)
WO (1) WO2022224184A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
CN119896633A (zh) * 2025-01-17 2025-04-29 中国人民解放军空军军医大学 一种水凝胶冷敷贴及其制备的冷热敷贴套装和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990026792A (ko) * 1997-09-26 1999-04-15 김윤 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
CN108697665A (zh) * 2015-09-30 2018-10-23 乔治·爱德华·霍格 局部镇痛性疼痛缓解制剂、其制备和使用方法
EP3538122B1 (en) * 2016-11-14 2025-03-26 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
US10966946B2 (en) * 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
BR112020014253A2 (pt) * 2018-01-12 2020-12-08 Nutrae, LLC Formulações de canabinóides encapsuladas para administração oral
CA3060926A1 (en) * 2018-09-06 2020-03-06 NuVessl, Inc. Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration
US20200197359A1 (en) * 2018-09-17 2020-06-25 Cody D. Freeze Cannabinoid and Terpene-Infused Topical Cream
US12403114B2 (en) * 2019-03-12 2025-09-02 Epm (Ip), Inc. Cannabinoid acid ester compositions and uses thereof
WO2020263643A1 (en) * 2019-06-28 2020-12-30 Nexzol Pharma, Inc. Transdermal formulations
AU2020358869A1 (en) * 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4041209A4 (en) * 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
US12016829B2 (en) * 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) * 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CA3155181A1 (en) * 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
CA3178878A1 (en) * 2020-04-20 2021-10-28 Fotios M. Plakogiannis Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20220047525A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
CN117337174A (zh) * 2020-12-03 2024-01-02 长矛治疗股份有限公司 用于治疗癌症的包含cbd或thc的透皮药物制剂

Also Published As

Publication number Publication date
US20220347151A1 (en) 2022-11-03
JP2024514362A (ja) 2024-04-01
WO2022224184A1 (en) 2022-10-27
EP4326252A4 (en) 2025-03-12
CA3215685A1 (en) 2022-10-27
EP4326252A1 (en) 2024-02-28
AU2022260813A1 (en) 2023-10-26
CN117545478A (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
UY39149A (es) Compuestos y métodos para el tratamiento de covid-19
CL2020000747A1 (es) Formulaciones de niraparib.
CO6571900A2 (es) Composiciones famaceúticas del compuesto espiro-oxindol para adminsitración tópica y sus usos como agentes terapeúticos
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
MX2020003381A (es) Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
MX2023012483A (es) Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
MX389553B (es) Composicion para incrementar la expresion de pgc-1alfa
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112018072201A2 (pt) composição compreendendo o componente à base de naftoquinona como ingrediente ativo, para prevenir ou melhorar a fadiga, cachexia, dor, declínio cognitivo e redução de células estaminais hematopoiéticas que são efeitos colaterais relacionados as drogas para tratamento anticancerígino
ECSP20078586A (es) Compuestos de azabencimidazol y productos farmacéuticos
MX2020005006A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
BR112022019486A2 (pt) Agente terapêutico para infecção por coronavírus
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
CO2020001881A2 (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco trometamina y clorhidrato de tramadol